The excellence of Daewoong Pharmaceutical’s Nabota showcased to international health care professionals at IMCAS Asia Class 2020

The excellence of Daewoong Pharmaceutical’s Nabota showcased to international health care professionals at IMCAS Asia Class 2020 - Shared the newest surgical techniques using Nabota via real-time live sessions - Participated in the 28th web symposium at MIPS 2020 on the 18th Daewoong Pharmaceutical (Daewoong) (CEO Sengho Jeon) announced on the 19th that Daewoong participated in IMCAS Asia Class 2020 and showcased the excellence of its botulinum toxin Nabota to members of the International Master Course on Aging Science (IMCAS). IMCAS Asia is a key international congress that is held by the IMCAS, which is one of the 3 key international societies for cosmetic surgery. The congress was held as a contactless online seminar to prevent the spread of COVID-19. During this symposium, which was held live at real-time, Daewoong had the opportunity to share the effectiveness of Nabota and the newest surgical methods with about 400 medical staff from the cosmetic surgery field from around the world. American dermatologist Dr. Hema Sundaram gave a session on “skin pore surgery through combination treatment using fillers and Nabota” as the senior instructor along with Wonwoo Choi, Director of WELLS Dermatology & Medical SPA. Hoseong Choi, Director of Piena Clinic, introduced “facial outline surgery through combination treatment using fillers and Nabota.” In the following video demonstration, Minhyeong Park, Director of Lamar Clinic, introduced “acne scar treatment through combination treatment using fillers and Nabota.” Dr. Hema Sundaram said, “Daewoong’s botulinum toxin formula is a product with 900 kDa, which has the same molecular structure as Botox, and has proven its noninferiority in comparison with Botox through large scale worldwide clinical tests.” “It is providing excellent effects and safety during its use in the field,” she added. Director Hoseong Choi then said, “Botulinum toxin formula products can be utilized in facial outline surgery and more through combination treatment using hyaluronic acid and fillers, which is popular among young people up to middle-aged people recently.” “I wish these networking opportunities can become a place of knowledge exchange where medical staff from around the world can learn various surgical techniques as well as surgery know-how,” he added. Furthermore, Daewoong also participated in the28th web symposium at MIPS 2020 on the 18th hosted by the Minimally Invasive Plastic Surgery (MIPS), an affiliation of the Korean Society of Plastic and Reconstructive Surgeons. Dr. Hema Sundaram, who led the special invitational lecture, gained attention by introducing “new surgical techniques for non-surgical facial outline and lifting using Nabota.” Seongsoo Park, head of Daewoong’s Neurotoxin Business Division, said, “It was a great opportunity to promote the excellence of Nabota.” “We will develop into a botulinum toxin brand by promoting our outstanding product power and technology to medical staff from across the globe that was proven by obtaining approval from strict regulatory agencies in the United States, Europe, and Canada,” he added. #  #  # [Photograph] Hoseong Choi, Director of Piena Clinic, participating in IMCAS Asia Class 2020’s webinar and introducing “facial outline surgery through combination treatment using fillers and Nabota.”

The release as fetched from its publisher. daewoong.co.kr ↗